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Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most frequent
cause of inherited Parkinson’s disease (PD). The most common PD-associated LRRK2
mutation, G2019S, induces increased production of reactive oxygen species in vitro. We
therefore hypothesized that individuals with PD-associated LRRK2 mutations might have
increased concentrations of oxidative stress markers and/or decreased total antioxidant
capacity (TAC) in their cerebrospinal fluid (CSF). We measured two oxidative stress
markers, namely 8-hydroxy-2′-deoxyguanosine (8-OHdG) and 8-isoprostane (8-ISO),
and TAC in CSF from LRRK2 mutation-bearing PD patients (LRRK2 PD = 19), sporadic
PD patients (sPD = 31), and healthy control subjects with or without these mutations
(LRRK2 CTL = 30, CTL = 27). 8-OHdG and 8-ISO levels were increased in LRRK2 CTL
subjects, while TAC was similar between groups. 8-ISO was negatively correlated, and
TAC was positively correlated, with Montreal Cognitive Assessment scores in LRRK2
PD, LRRK2 CTL, and CTL subjects. Correlations in both groups of PD patients between
the two oxidative stress markers and Unified Parkinson Disease Rating Scale Total
scores were weak, while TAC was negatively correlated with these scores. These
findings suggest that oxidative stress may be increased in the CNS in healthy individuals
with PD-associated LRRK2 mutations. Further, TAC may decrease in the CNS with the
progression of PD, and when cognitive impairment is present regardless of the presence
or absence of PD.
Keywords: 8-isoprostane, 8-hydroxydeoxyguanosine, LRRK2, oxidative stress, Parkinson’s disease, total
antioxidant capacity
INTRODUCTION
Parkinson’s disease (PD) is most commonly a sporadic disorder, but up to 10% of PD cases are
associated with genetic mutations (Van Den Eeden et al., 2003). The main neuropathological
finding in PD is extensive loss of dopaminergic neurons whose cell bodies are located in the
substantia nigra pars compacta (SNC) and whose axons project to the striatum (Davie, 2008).
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Increases in lipid, protein, and nucleic acid oxidation have been
reported in the PD SNC (Dexter et al., 1994; Yoritaka et al.,
1996; Alam et al., 1997; Floor and Wetzel, 1998; Zhang et al.,
1999) suggesting that oxidative stress (overproduction of reactive
oxygen and nitrogen species relative to their detoxification
mechanisms [Wang and Michaelis, 2010]) may play a role in
the loss of dopaminergic neurons (Götz et al., 1990; Spencer
et al., 1994; Dias et al., 2013). Factors thought to contribute to
increased oxidative stress in the PD brain include mitochondrial
dysfunction (Schapira, 2008), dysregulated iron metabolism
(Dexter et al., 1989), neuroinflammation (Peterson and Flood,
2012), decreased antioxidant levels (Perry et al., 1982), and
elevated production of H2O2 and reactive oxygen species (ROS)
as a consequence of increased dopamine turnover (Fahn and
Cohen, 1992).
Mutations in the gene encoding for leucine-rich repeat kinase
2 (LRRK2) are the most frequent known cause of inherited PD
in most populations (Vilas et al., 2016). The role of LRRK2
protein is incompletely understood; it possesses kinase and
GTPase activities, and has been associated with autophagy,
mitochondrial functions, and microtubule/cytoskeletal dynamics
(Wallings et al., 2015; Esteves and Cardoso, 2016; Kang and
Marto, 2016). Expression of the most common PD-associated
LRRK2 mutation, G2019S (Kachergus et al., 2005), may uncouple
mitochondrial oxidative phosphorylation (Mortiboys et al.,
2010; Papkovskaia et al., 2012) and increase intracellular ROS
production in vitro (Pereira et al., 2014). These findings suggest
that this LRRK2 mutation might increase CNS oxidative stress in
healthy individuals, and/or contribute to oxidative stress in PD
patients carrying this mutation. The interaction between LRRK2
and oxidative stress may be bidirectional, because oxidative
stress has been shown to promote in vitro dephosphorylation
of LRRK2 at Ser910/Ser935, causing loss of its ability to bind
to 14-3-3 proteins (Mamais et al., 2014). 14-3-3 proteins bind
to serine/threonine-phosphorylated residues, often functioning
as direct regulators of the target proteins to which they bind
(reviewed by Tzivion et al., 2001). Because LRRK2’s binding
to 14-3-3 controls its cellular localization, decrease in this
binding results in cellular translocation of LRRK2, causing it
to accumulate within cytoplasmic pools (Dzamko et al., 2010;
Mamais et al., 2014).
8-hydroxy-2′-deoxyguanosine (8-OHdG) (Valavanidis et al.,
2009) and 8-isoprostane (8-ISO) (Morrow et al., 1992) are
commonly measured oxidative stress markers. In contrast to
these direct indicators of oxidative stress, total antioxidant
capacity (TAC) has been suggested to be a possible indirect
marker for this condition (Mandrioli et al., 2006). TAC
includes antioxidant activities of non-enzymatic low molecular
weight substances such as glutathione, ascorbic acid, uric acid,
α-tocopherol, and coenzyme Q (Alho et al., 1998; Bartosz, 2003);
a reduction in TAC could alter the balance between ROS levels
and mechanisms which protect against their cytotoxic effects,
in favor of oxidative damage. The concentration of 8-OHdG
has been reported to be increased in PD cerebrospinal fluid
(CSF) (Kikuchi et al., 2002; Abe et al., 2003; Gmitterová et al.,
2009; Isobe et al., 2010). We found no reports of 8-ISO or TAC
measurements in PD CSF; however, 8-ISO in the PD SNC has
been reported to be unchanged (Fessel et al., 2003), while TAC
in the PD SNC is reported to be decreased (Sofic et al., 2006).
The primary objective of this study was therefore to compare
the concentrations of 8-OHdG, 8-ISO, and TAC in CSF between
LRRK2 PD, sPD, LRRK2 CTL, and CTL subjects. Our secondary
objective was to examine the associations in these individuals
of the CSF oxidative stress markers and TAC with cognitive
functioning levels, and, in the two groups of PD patients, with
clinical disease duration and progression.
MATERIALS AND METHODS
Study Subjects
The subjects who participated in this study (LRRK2 PD = 19,
sPD = 31, LRRK2 CTL = 30, CTL = 27) were recruited
at St. Olav’s Hospital, Trondheim, Norway by neurologist
Jan Aasly, M.D. The study was approved by the Regional
Committee for Medical Research Ethics, Central Norway, for
the procedures done at St. Olav’s Hospital (subject recruitment
and obtaining of CSF samples), and was given exempt status
by the Institutional Review Board of Beaumont Health (Royal
Oak, MI, USA). All procedures relating to the subjects in the
study, including obtaining of written informed consent prior to
performing lumbar punctures, were performed in accordance
with the Declaration of Helsinki and its subsequent amendments.
Measurements of 8-OHdG, 8-ISO, and TAC were performed
in the Neurology Research Laboratory at Beaumont Hospital-
Royal Oak (Royal Oak, MI, USA). The diagnosis of PD was
made on the basis of consensus clinical criteria (Gelb et al.,
1999). The diagnosis of sPD was established by clinical history
and neurological findings compatible with PD, plus lack of
evidence, upon screening of whole blood-extracted DNA with
standard techniques including exome sequencing (Bras and
Singleton, 2011), for known PD-related mutations including
those identified in the PARK8 (LRRK2), PARK2, PARK7, PINK1,
DNAJC13, and SNCA genes. (All study subjects were screened
for these mutations.) All 30 LRRK2 CTL subjects carried the
G2019S gene mutation; 17 of the 19 LRRK2 PD patients also
carried this mutation, while the other two carried the N1437H
mutation (Aasly et al., 2010). Unified Parkinson’s Disease Rating
Scale (UPDRS) Total and Part 3 (Motor) scores were measured
the same day that CSF was obtained, and Montreal Cognitive
Assessment (MoCA) scores were measured the day of CSF
collection or the following day. The UPDRS (Fahn et al., 1987)
measures overall Parkinsonian disability; it includes 42 items,
with a total possible score of 199 points (0 points = no
disability; 199 points = worst possible disability). In addition to
UPDRS Total scores, UPDRS Part 3, which includes 14 items
and assesses motor abnormalities, is often used by clinicians
to monitor PD progression. MoCA is a screening test for
cognitive impairment with a 30 point scale, with scores > 26
considered to be in the normal range (Nasreddine et al., 2005;
Smith et al., 2007). Collection of CSF specimens followed
standardized procedures used by the Parkinson’s Progression
Markers Initiative (Parkinson’s Progression Markers Initiative,
2014).
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TABLE 1 | Summaries of demographic and clinical characteristics for diagnostic groups.
Variable LRRK2 PD (n = 19) sPD (n = 31) LRRK2 CTL (n = 30) CTL (n = 27)
Age, years Mean (SD) 61.4 (10.5) 60.5 (7.9) 62.3 (10.7) 61.5 (9.3)
% Males 21 48 40 37
MoCA scores Median (range) 27 (16−29) 27 (12−30) 27 (20−30) 29 (26−30)
UPDRS Total scores Median (range) 25 (20−75) 27 (16−55) 0 (0−7) 0 (0−0)
UPDRS Part 3 scores Median (range) 19 (13−49) 20 (12−39) 0 (0−7) 0 (0−0)
Clinical duration, years Median (range) 5 (0–21) 3 (0–25) NA NA
The four groups were well matched for age and gender distribution, except that the LRRK2 PD group had a lower proportion of males. Median MoCA scores were
highest in the CTL group (MoCA scores 26–30 are considered to be normal, while scores below 26 suggest cognitive impairment). UPDRS scores were similar between
the PD groups (increasing UPDRS scores indicate worsening Parkinsonian disability), while the duration of clinical disease was slightly longer for LRRK2 PD than for sPD
patients. (LRRK2 PD, Parkinson’s disease patients with LRRK2 mutations; sPD, sporadic Parkinson’s disease patients; LRRK2 CTL, healthy control subjects with LRRK2
mutations; CTL, healthy control subjects without known PD-associated mutations; MoCA, Montreal Cognitive Assessment; UPDRS, Unified Parkinson’s Disease Rating
Scale; NA, not applicable).
Measurements of CSF 8-OHdG, 8-ISO,
and TAC
8-OHdG, 8-ISO, and TAC were measured in CSF using kits
from Cayman Chemicals (Ann Arbor, MI, USA): DNA/RNA
Oxidative Damage ELISA (cat. # 589320, 8-Isoprostane ELISA
(cat. # 516351), and Antioxidant Assay Kit (cat. # 709001).
[The DNA/RNA Oxidative Damage ELISA measures 8-OHdG,
8-hydroxyguanosine (8-OHG), and 8-hydroxyguanine; the
measurements, using this kit, on CSF samples in this study
will be referred to as 8-OHdG]. The detection limits for the
8-OHdG, 8-ISO, and TAC kits were stated by the manufacturer
to be 30 pg/mL, 2.7 pg/mL, and 44 µM (Trolox equivalents)
respectively. The standard curves for the 8-OHdG, 8-ISO, and
TAC assays ranged from 10.3 pg/mL to 3,000 pg/mL, 0.8 pg/mL
to 500 pg/mL, and 0.045 mM to 0.330 mM Trolox equivalents,
respectively. 8-OHdG and 8-ISO were measured in duplicate
after diluting CSF samples 1:4 and 1:2 respectively with EIA
buffer, while TAC was measured in duplicate in undiluted CSF
samples. The kits included standards used to generate standard
curves, which were plotted using Softmax Pro software (version
3.0; Molecular Devices Corp., Sunnyvale, CA, USA). The
concentrations of 8-OHdG, 8-ISO, and TAC in each CSF sample
were then calculated with Softmax based upon where their
optical density values fell on the standard curves. Concentrations
of 8-OHdG, 8-ISO, and TAC used in statistical analyses were
means of duplicate measurements.
Statistical Procedures
Categorical variables were summarized by counts with
percentages. Normality of the data was assessed using box
plots and normal probability plots. Variables which were not
reasonably normal were summarized by medians and ranges.
Comparisons between the four diagnostic groups for 8-OHdG,
8-ISO, and TAC used the non-parametric Kruskal–Wallis
test, while multiple comparison testing was done with a
non-parametric procedure, the Dwass, Steele, Critchlow-Fligner
(DSCF) procedure. P-values less than 0.05 were accepted as
statistically significant. Spearman’s rank-order correlation
coefficient (Spearman’s rho) measured the associations of
8-OHdG, 8-ISO, and TAC with subject age and MoCA scores in
each of the four groups, and the associations of the two oxidative
FIGURE 1 | Distribution of 8-OHdG concentrations in diagnostic
groups. Means (circle), medians (line through center of box), upper and lower
quartiles (upper and lower borders of box, respectively), most extreme
non-outlier values (lines extending from box), and outliers (asterisks) are
shown for 8-OHdG concentrations in CSF specimens from LRRK2 PD, sPD,
LRRK2 CTL, and CTL subjects. The Kruskal–Wallis p-value for the overall test
of between-group differences for 8-OHdG was 0.04. The only pairwise
difference which achieved p < 0.05 with the DSCF procedure was the
comparison of 8-OHdG between the LRRK2 CTL and sPD groups (p = 0.03).
(LRRK2 PD, Parkinson’s disease subjects carrying LRRK2 gene mutations;
sPD, sporadic Parkinson’s disease; LRRK2 CTL, healthy control subjects
carrying PD-associated LRRK2 gene mutations; CTL, healthy control subjects
lacking detectable PD-associated gene mutations).
stress markers and TAC with UPDRS scores and duration of
clinical disease in each of the two groups of PD patients. The SAS
System for Windows version 9.3 (SAS Institute Inc., Cary, NC,
USA) was used for statistical analysis, and Minitab 14 (Minitab,
State College, PA, USA) was used for graphs.
RESULTS
Study Subjects
The subjects in this study consisted of 66 women (62%) and 41
men (38%) with a mean age of 61.4 years (SD= 9.5; range 44–85).
Summary statistics of demographic and clinical characteristics
for the diagnostic groups are shown in Table 1. The four groups
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FIGURE 2 | Distribution of 8-ISO concentrations in diagnostic groups.
Means (circle), medians (line through center of box), upper and lower quartiles
(upper and lower borders of box, respectively), most extreme non-outlier
values (lines extending from box), and outliers (asterisks) are shown for 8-ISO
concentrations in CSF specimens from LRRK2 PD, sPD, LRRK2 CTL, and
CTL subjects. The Kruskal–Wallis p-value for the overall test of between-group
differences for 8-ISO was 0.03. None of the pairwise differences had p-values
less than 0.05 using the DSCF procedure (p = 0.06 for comparison of 8-ISO
levels between LRRK2 CTL and sPD). (LRRK2 PD, Parkinson’s disease
subjects carrying LRRK2 gene mutations; sPD, sporadic Parkinson’s disease;
LRRK2 CTL, healthy control subjects carrying PD-associated LRRK2 gene
mutations; CTL, healthy control subjects lacking detectable PD-associated
gene mutations).
FIGURE 3 | Distribution of TAC concentrations in diagnostic groups.
Means (circle), medians (line through center of box), upper and lower quartiles
(upper and lower borders of box, respectively), most extreme non-outlier
values (lines extending from box), and outliers (asterisks) are shown for TAC
concentrations in CSF specimens from LRRK2 PD, sPD, LRRK2 CTL, and
CTL subjects. The Kruskal–Wallis p-value for the overall test of between-group
differences for TAC was 0.82. (LRRK2 PD, Parkinson’s disease subjects
carrying LRRK2 gene mutations; sPD, sporadic Parkinson’s disease; LRRK2
CTL, healthy control subjects carrying PD-associated LRRK2 gene mutations;
CTL, healthy control subjects lacking detectable PD-associated gene
mutations).
were well balanced for age (p = 0.90). Gender distribution was
similar between sPD, LRRK2 CTL, and CTL subjects (48, 40, and
37% men) but the LRRK2 PD group had a lower proportion of
men (21%). MoCA scores tended to be higher in the CTL group
than in the other groups; the CTL group median was 29 while for
each of the other groups the median was 27. (The p-value for the
Kruskal–Wallis test comparing the MoCA scores between groups
was <0.001; the DCSF p-values for all multiple comparisons
involving the control group were≤0.022.) UPDRS Total and Part
3 (Motor) scores were similar between the sPD and LRRK2 PD
patients, but the median duration of clinical disease was longer
for LRRK2 PD patients (5 years) than for sPD patients (3 years)
(p= 0.04).
CSF 8-OHdG, 8-ISO, and TAC
Concentrations
Summary statistics for 8-OHdG, 8-ISO, and TAC concentrations
in the four diagnostic groups are shown graphically in boxplots
in Figures 1–3. The Kruskal–Wallis p-values for overall tests
of between-group differences were 0.04 for 8-OHdG, 0.03 for
8-ISO, and 0.82 for TAC. The median values for 8-OHdG and
8-ISO levels were higher in the LRRK2 CTL group than in
the other groups (by 12–16% for 8-OHdG and by 20–38% for
8-ISO), but the only pairwise difference which was significant
at the 0.05 level with the DCSF procedure was the comparison
of 8-OHdG concentrations between the LRRK2 CTL and sPD
groups (p = 0.03). [The p-values for comparing 8-ISO levels
between the LRRK2 CTL and each of the other three groups
were < 0.20, including 0.06 for the comparison between the
LRRK2 CTL and sPD groups. Conversely, all p-values for pairwise
comparisons between the other three groups (i.e., excluding the
LRRK2 CTL group) for 8-OHdG and for 8-ISO were > 0.70]. In
contrast to 8-OHdG and 8-ISO, the median values for TAC were
extremely similar between groups, with a difference of only 2.4%
between the largest and smallest values.
Correlations in All Diagnostic Groups
between 8-OHdG, 8-ISO, TAC, Age, and
MoCA Scores
The Spearman rank-order correlations between the pairs of
variables examined in all four diagnostic groups (8-OHdG,
8-ISO, TAC, age, and MoCA scores) are shown in Table 2 with
their respective p-values. The concentrations of both oxidative
stress markers were positively correlated with age in the control
groups, and 8-OHdG was positively correlated with age in the
LRRK2 PD subjects. 8-ISO was negatively correlated with MoCA
scores in LRRK2 PD, LRRK2 CTL, and CTL subjects, while TAC
was positively correlated with MoCA scores in these groups.
MoCA scores were negatively correlated with age in LRRK2 CTL,
sPD, and CTL subjects.
Correlations in PD Patients between
8-OHdG, 8-ISO, TAC, and MoCA Scores
With UPDRS Scores and Clinical Disease
Duration
Table 3 shows the Spearman rank-order correlations and their
respective p-values for both groups of PD patients between 8-
OHdG, 8-ISO, TAC, and MoCA scores with UPDRS scores
and duration of clinical disease. Correlations of 8-OHdG and
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TABLE 2 | Correlations in all diagnostic groups between 8-OHdG, 8-ISO, TAC, age, and MoCA scores.
Association LRRK2 PD sPD LRRK2 CTL CTL
8-OHdG vs. age 0.51 (0.02) 0.13 (0.48) 0.63 (0.0002) 0.41 (0.03)
8-ISO vs. age −0.21 (0.39) −0.18 (0.34) 0.36 (0.05) 0.45 (0.02)
TAC vs. age −0.17 (0.48) −0.06 (0.76) 0.12 (0.52) −0.19 (0.35)
MoCA vs. age −0.03 (0.89) −0.47 (0.008) −0.51 (0.004) −0.31 (0.12)
8-OHdG vs. 8-ISO −0.21 (0.39) 0.37 (0.04) 0.28 (0.13) 0.30 (0.13)
8-OHdG vs. TAC −0.16 (0.52) 0.05 (0.80) −0.12 (0.52) −0.02 (0.91)
8-ISO vs. TAC −0.28 (0.25) −0.03 (0.86) 0.05 (0.77) −0.20 (0.32)
8-OHdG vs. MoCA −0.18 (0.46) −0.20 (0.27) −0.29 (0.12) −0.11 (0.59)
8-ISO vs. MoCA −0.35 (0.15) −0.17 (0.37) −0.30 (0.11) −0.51 (0.007)
TAC vs. MoCA 0.50 (0.028) 0.14 (0.46) 0.41 (0.023) 0.56 (0.003)
Correlations between pairs of variables examined in all four diagnostic groups are shown (Spearman rho values), with p-values in parentheses. Both oxidative stress
markers were positively correlated with age in the control groups, and 8-OHdG was positively correlated with age in LRRK2 PD patients. 8-ISO was negatively correlated
with MoCA scores in LRRK2 PD, LRRK2 CTL, and CTL subjects, while TAC positively correlated with MoCA scores in these groups. MoCA scores were negatively
correlated with age in LRRK2 CTL, sPD, and CTL subjects. (8-OHdG, 8-hydroxy-2′-deoxyguanosine; 8-ISO, 8-isoprostane; TAC, total antioxidant capacity; LRRK2 PD,
Parkinson’s disease patients with LRRK2 mutations; sPD, sporadic Parkinson’s disease patients; LRRK2 CTL, healthy control subjects with LRRK2 mutations; CTL,
healthy control subjects without known PD-associated mutations; MoCA, Montreal Cognitive Assessment).
TABLE 3 | Correlations in PD patients between 8-OHdG, 8-ISO, TAC, and
MoCA scores with UPDRS scores and clinical disease duration.
Association LRRK2 PD sPD
8-OHdG vs. UPDRS Total score −0.14 (0.56) −0.18 (0.33)
8-OHdG vs. UPDRS Part 3 score −0.11 (0.65) −0.22 (0.22)
8-OHdG vs. clinical duration −0.12 (0.62) −0.39 (0.03)
8-ISO vs. UPDRS Total score 0.10 (0.69) 0.17 (0.35)
8-ISO vs. UPDRS Part 3 score 0.14 (0.56) 0.10 (0.61)
8-ISO vs. clinical duration 0.24 (0.32) −0.24 (0.20)
TAC vs. UPDRS Total score −0.33 (0.17) −0.41 (0.02)
TAC vs. UPDRS Part 3 score −0.30 (0.21) −0.20 (0.29)
TAC vs. clinical duration −0.11 (0.64) −0.37 (0.04)
MoCA score vs. UPDRS Total score −0.30 (0.22) −0.49 (0.005)
MoCA score vs. UPDRS Part 3 score −0.27 (0.27) −0.33 (0.07)
MoCA score vs. clinical duration −0.38 (0.11) −0.18 (0.33)
For the two groups of PD patients, the correlations (Spearman rho values) of
8-OHdG, 8-ISO, TAC, and MoCA scores with UPDRS scores and duration of
clinical disease are shown, with p-values in parentheses. TAC was negatively
correlated with UPDRS Total scores in both PD groups. 8-OHdG and TAC were
negatively correlated with clinical duration in sPD patients, and MoCA scores were
negatively associated with UPDRS scores in this group. (8-OHdG, 8-hydroxy-2′-
deoxy-guanosine; 8-ISO, 8-isoprostane; TAC, total antioxidant capacity; LRRK2
PD, Parkinson’s disease patients with LRRK2 mutations; sPD, sporadic Parkinson’s
disease patients; LRRK2 CTL, healthy control subjects with LRRK2 mutations; CTL,
healthy control subjects without known PD-associated mutations; MoCA, Montreal
Cognitive Assessment; UPDRS, Unified Parkinson’s Disease Rating Scale).
8-ISO with both UPDRS scores were weak, but TAC levels were
negatively correlated with UPDRS Total scores. MoCA scores
were negatively correlated with UPDRS Total and Part 3 scores
in sPD patients.
DISCUSSION
Previous studies of 8-OHdG and/or 8-OHG levels in PD CSF,
summarized in Table 4, found their concentrations to be
increased relative to control CSF (Kikuchi et al., 2002; Abe et al.,
2003; Gmitterová et al., 2009; Isobe et al., 2010). No information
was provided in these studies regarding possible PD-related gene
mutations in the study subjects. The control subjects were healthy
volunteers except in the study by Gmitterová et al. (2009), in
which the controls were non-cognitively impaired subjects with
neurological problems other than PD. In that study PD patients
with cognitive impairments (indicated by Mini Mental State
Examination [MMSE] scores < 27) had lower CSF 8-OHdG
levels than PD patients without cognitive impairments; only
when the analysis was limited to the latter group of PD patients
was the difference in the levels of 8-OHdG between the PD and
control subjects statistically significant.
Our findings in the present study do not confirm the
earlier reports of increased 8-OHdG in PD CSF. Methodological
differences (HPLC vs. ELISA, measurement of 8-OHdG vs.
8-OHG) and/or characteristics of the PD subjects (differences
in medication, age, clinical disease duration, or severity) may
have contributed to these conflicting results. Chance variation
as a consequence of the small sample sizes in some of the
previous studies could also have been a factor; the studies of
Abe et al. (2003) and Gmitterová et al. (2009) included only 15
and 13 control subjects respectively. The median concentrations
of 8-OHdG in our groups were similar to those reported by
Gmitterová et al. (2009) and half to one-third of those reported
by Kikuchi et al. (2002); these latter two studies also used ELISA
to measure 8-OHdG, whereas Abe et al. (2003) and Isobe et al.
(2010) employed HPLC. The 8-OHdG levels reported by Isobe
et al. (2010) were far lower than ours, while the study by Abe et al.
(2003) measured 8-OHG but not 8-OHdG so no comparison can
be made to our measurements.
In contrast to the findings of Gmitterová et al. (2009)
discussed above, we found no evidence that cognitive deficits
were associated with lower 8-OHdG levels in our PD patients.
Our analysis suggested only weak correlations between MoCA
scores and 8-OHdG levels for both groups of PD patients (rho
values = −0.20 for sPD patients and −0.18 for LRRK2 PD
patients). A similar trend was seen with 8-ISO; the correlations
between MoCA scores and 8-ISO were −0.17 for our sPD
Frontiers in Aging Neuroscience | www.frontiersin.org 5 April 2017 | Volume 9 | Article 89
fnagi-09-00089 March 30, 2017 Time: 13:59 # 6
Loeffler et al. LRRK2 Mutation CSF Oxidative Stress
TABLE 4 | Previous studies of 8-OHdG and/or 8-OHG in PD CSF.
Kikuchi et al., 2002 Abe et al., 2003 Gmitterová et al., 2009 Isobe et al., 2010
Study subjects 31 PD, 16 MSA, 29 controls 24 PD, 15 controls 27 PD without dementia, 21 PD
with dementia, 18 LBD, 18 AD,
13 non-demented neurological
controls
20 PD, 20 controls
Variable measured “8-OHdG/8-OHG”
( = 8-OHdG + 8-OHG)
8-OHG 8-OHdG 8-OHdG
Method ELISA (in-house) HPLC ELISA (IBL Transatlantic) HPLC
Results PD: 2.85 ± 2.43 ng/mL; MSA:
4.24 ± 3.53 ng/mL;
Controls: 1.46 ± 0.83 ng/mL
PD: 288 ± 129 pM
(86.1 ± 38.6 pg/mL);
Controls: 97 ± 32 pM
(29.0 ± 11.5 pg/mL)
PD: 1.0 ± 0.45 ng/mL; PD with
dementia: 0.90 ± 0.38 ng/mL;
LBD: 0.83 ± 0.25 ng/mL;
AD: 0.89 + 0.47 ng/mL;
Controls: 0.71 ± 0.29 ng/mL
PD: 5.8 ± 4.5 pg/mL;
Controls: 1.8 ± 0.6 pg/mL
Conclusions PD > Controls (p < 0.0005) PD > Controls (p < 0.001) PD without
dementia > non-demented
neurological Controls (p = 0.03)
PD > Controls (p < 0.0001)
Two studies measured 8-OHdG, one measured 8-OHG, and one measured both variables. The methods for these measurements included in-house ELISA, commercial
ELISA, and HPLC. Results are shown as means and SDs. The range of measurements for 8-OHdG concentrations varies widely between the studies. (PD, Parkinson’s
disease; MSA, multiple system atrophy; LBD, Lewy body dementia; AD, Alzheimer’s disease; HPLC, high performance liquid chromatography).
patients and−0.35 for our LRRK2 PD patients. When we divided
our two PD groups into cognitively impaired subjects (MoCA
scores < 26) and non-cognitively impaired subjects (MoCA
scores > 26), we similarly found no evidence that cognitive
deficits lowered the CSF levels of 8-OHdG or 8-ISO in either PD
group (data not shown).
An intriguing finding in this study was that both 8-OHdG and
8-ISO concentrations were increased in our LRRK2 CTL group
compared to our other diagnostic groups (p-values for overall
tests of between-group differences= 0.04 and 0.03, respectively).
Although we anticipated that LRRK2 mutations might increase
CSF oxidative stress markers in both healthy individuals and in
PD patients carrying these mutations, we detected the expected
increase only in our LRRK2 CTL subjects; why a similar increase
was not found in our LRRK2 PD patients is unclear. To our
knowledge, this study is the first to investigate CNS oxidative
stress in individuals with LRRK2 mutations, so our findings
require confirmation with a larger cohort.
Whether the increases in 8-OHdG and 8-ISO that we
detected in our LRRK2 CTL subjects (by 12–16% and 20–38%,
respectively) are of biological significance is unknown. Of
relevance to our results is a report that CSF concentrations
of α-synuclein soluble oligomers, suggested to be the most
neurotoxic α-synuclein conformation (Winner et al., 2011), are
also increased in healthy subjects with PD-associated LRRK2
mutations compared to healthy controls lacking these mutations
(Aasly et al., 2014). While oxidative stress has been suggested to
be a mechanism by which soluble α-synuclein oligomers may
exert their neurotoxic effects (Roberts and Brown, 2015; Deas
et al., 2016), we do not know if our finding of increased CSF
oxidative stress markers in our LRRK2 CTL subjects may be
related to elevated CSF levels of soluble α-synuclein oligomers in
these individuals.
Our other findings in this study related to TAC. The observed
correlations of TAC with 8-OHdG and 8-ISO were weak, so
our results do not support the suggestion of Mandrioli et al.
(2006) that TAC may be an indirect indicator of oxidative stress.
We found no evidence for differences in CSF TAC activity
between PD patients and control subjects with or without LRRK2
mutations. This result agrees with an earlier report that the
concentration of ascorbate, the main hydrophilic antioxidant in
CSF (Lönnrot et al., 1996) and main contributor to CSF TAC
activity (Alho et al., 1998; Lönnrot et al., 1996), is unchanged in
PD CSF (Buhmann et al., 2004). Our finding of similar CSF TAC
levels between PD patients and control subjects suggests that the
decreased TAC activity reported in the PD SNC (Sofic et al., 2006)
may not be reflected by TAC levels in PD CSF.
We found positive correlations between CSF TAC and MoCA
scores for three of our groups (LRRK2 PD, LRRK2 CTL, and CTL
subjects). This suggests that TAC in CSF may decrease as MoCA
scores decrease (e.g., as cognitive deficits develop), regardless of
the presence or absence of PD. This result is similar to the finding
by Bassett et al. (1999) that CSF antioxidant capacity is reduced
in patients with Alzheimer’s disease.
Our TAC results included some PD-specific findings. TAC
was negatively correlated with UPDRS Total scores in both
groups of PD patients. Because an increase in UPDRS scores
indicates worsening Parkinsonian disability, these correlations
suggest the possibility that TAC may decrease in the CNS during
the progression of PD.
The numbers of CSF samples available to us were a limitation
with respect to our ability to identify the locations of group
differences for 8-OHdG, 8-ISO, and TAC with the DCSF
procedure, and the associations between their concentrations
and the other variables we examined. A second limitation is
that the concentrations of these oxidative stress markers in
our PD patients, although not increased compared to our
control subjects, could potentially have been influenced by the
prooxidative effect of their levodopa therapy (Buhmann et al.,
2004).
We conclude that the concentrations of oxidative stress
markers in CSF may be increased in healthy individuals with
Frontiers in Aging Neuroscience | www.frontiersin.org 6 April 2017 | Volume 9 | Article 89
fnagi-09-00089 March 30, 2017 Time: 13:59 # 7
Loeffler et al. LRRK2 Mutation CSF Oxidative Stress
PD-associated LRRK2 mutations. If our findings in this study
can be confirmed with larger group sizes, then the possibility
should be considered that an increase in CNS oxidative stress
in individuals carrying these mutations may contribute to
their risk for developing PD. We also conclude that TAC
levels may decrease during the progression of PD, and in the
presence of impaired cognitive functioning irrespective of PD
status.
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